Buy Like Buffett
Watchlist

Flagship explainer

How Crinetics Pharmaceuticals, Inc. makes its money

Start with a dollar of revenue and follow what the filing says remains.

revenueBranching filed flows with values and percentages directly labeled. Missing filing concepts are omitted rather than estimated.Revenue$7.7M · 100%Cost of revenue$1.1M · 14%Gross profit$6.6M · 86%Operating income−$517M · −6715%Income before tax−$465M · −6044%Income tax$180000 · 2%Net income−$465M · −6046%As of 2025-12-31 · 1 SEC filing sourceBuy Like Buffett · buylikebuffett.com

Honest partial: the filing did not provide a normalized tag for Research and development, Selling, general and administrative; those components are omitted, not plugged.

Table alternative
Filed lineValue% of revenueSource
$7.7M100%
  • 10-K · FY 2025Filing detailsAccession 0001658247-26-000012 · filed Feb 26, 2026
Cost of revenue$1.1M14%
  • 10-K · FY 2025Filing detailsAccession 0001658247-26-000012 · filed Feb 26, 2026
$6.6M86%
  • 10-K · FY 2025Filing detailsAccession 0001658247-26-000012 · filed Feb 26, 2026
−$517M−6715%
  • 10-K · FY 2025Filing detailsAccession 0001658247-26-000012 · filed Feb 26, 2026
Income before tax−$465M−6044%
  • 10-K · FY 2025Filing detailsAccession 0001658247-26-000012 · filed Feb 26, 2026
Income tax$1800002%
  • 10-K · FY 2025Filing detailsAccession 0001658247-26-000012 · filed Feb 26, 2026
−$465M−6046%
  • 10-K · FY 2025Filing detailsAccession 0001658247-26-000012 · filed Feb 26, 2026
Source:
  • 10-K · FY 2025Filing detailsAccession 0001658247-26-000012 · filed Feb 26, 2026
· event Dec 31, 2025 · retrieved Sep 30, 2026 · annual-row source set
Embed this chart

View the full Crinetics Pharmaceuticals, Inc. analysis at Buy Like Buffett